New Class of Cancer Vaccine Based on an Off-The-Shelf Antigen Presenting Cell line (PDC*line)
Time: 9:30 am
day: Day Two
Details:
- PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
- PDC*line is much more potent to prime and boost antitumour antigen, including neoantigens, specific cytotoxic T cells than conventional vaccines and improves the response to checkpoint inhibitors
- The technology can be applied for any cancer
